Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #100
Alam, RM; Keating, JJ. Adding more “spice” to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. Drug Test. Anal., 1 Mar 2020, 12 (3), 297–315. 2.8 MB. https://doi.org/10.1002/dta.2752 #90 Structure 71 has a single bond where a double bond belongs
Kevin, RC; Mirlohi, S; Manning, JJ; Boyd, R; Cairns, EA; Ametovski, A; Lai, F; Luo, JL; Jorgensen, W; Ellison, R; Gerona, RR; Hibbs, DE; McGregor, IS; Glass, M; Connor, M; Bladen, C; Zamponi, GW; Banister, SD. Putative synthetic cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and their analogues are T-type calcium channel (CaV3) inhibitors. ACS Chem. Neurosci., 4 May 2022, 13 (9), 1395–1409. 4.5 MB. https://doi.org/10.1021/acschemneuro.1c00822 #20 MS,NMR